Basic information
- Name:
Epirubicin hydrochloride
- CAS No.:
56390-09-1
- Molecular Structure:
- Formula:
- C27H29NO11.HCl
- Molecular Weight:
- 579.99
- Synonyms:
- 5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S,10S)- (9CI);5,12-Naphthacenedione,10-[(3-amino-2,3,6-trideoxy-a-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-,hydrochloride, (8S-cis)-;4'-Epidoxorubicin hydrochloride;4'-epi-Adriamycinhydrochloride;Ellence;Epidoxorubicin hydrochloride;
- EINECS:
- 260-145-2
- Density:
- 1.61 g/cm3
- Melting Point:
- 185 °C dec
- Boiling Point:
- 810.3 °C at 760 mmHg
- Flash Point:
- 443.8 °C
- Appearance:
- Orange-red crystalline solid
Famous Chemical Enterprises
-
Livzon -
Total -
Shell -
Dupont -
Exxonmobil -
Akzonobel -
Basf -
Bayer -
BP
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
Chemistry
IUPAC Name: (7S,9S)-7-[(2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione hydrochloride
Synonyms of Epirubicin hydrochloride (CAS NO.56390-09-1): (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside hydrochloride ; 4'-Epidoxorubicin hydrochloride ; 4'-Epi-Adriamycin hydrochloride ; Epidoxorubicin hydrochloride ; Farmorubicin ; Pharmorubicin
CAS NO: 56390-09-1
Molecular Formula: C27H29NO11.HCl
Molecular Weight: 579.99
Molecular Structure: 
EINECS: 260-145-2
Flash Point: 443.8 °C
Enthalpy of Vaporization: 123.51 kJ/mol
Boiling Point: 810.3 °C at 760 mmHg
Vapour Pressure: 9.64E-28 mmHg at 25°C
Melting Point: 185°C dec
Appearance: Orange-Red Crystalline Solid
Product Categories of Epirubicin hydrochloride (CAS NO.56390-09-1): Antibiotics;Intermediates & Fine Chemicals;Pharmaceuticals
Uses
Epirubicin hydrochloride (CAS NO.56390-09-1) is used as an antineoplastic mainly used for treatment of acute and chronic leukemia, malignant lymphoma.
Toxicity Data With Reference
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD50 | intravenous | 2250ug/kg (2.25mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
| mouse | LD50 | intravenous | 31500ug/kg (31.5mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
| mouse | LD50 | oral | > 2gm/kg (2000mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
| mouse | LD50 | subcutaneous | 37500ug/kg (37.5mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
| rat | LD50 | intraperitoneal | 10800ug/kg (10.8mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
| rat | LD50 | intravenous | 17mg/kg (17mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 26, Pg. 740, 1995. | |
| rat | LD50 | oral | 1350mg/kg (1350mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
| rat | LD50 | subcutaneous | 17600ug/kg (17.6mg/kg) | Drugs in Japan Vol. -, Pg. 200, 1990. | |
| women | TDLo | intravenous | 1622mg/kg (1622mg/kg) | SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS | Lancet. Vol. 2, Pg. 629, 1986. |